FDA Advisory Panel to Evaluate Arcoxia, a Vioxx Replacement

By Christine Miller, Health Guide Wednesday, April 11, 2007

- A
- A
- A

I will be watching for the FDA advisory panel to make its recommendation on Thursday. It should be noted that advisory panel recommendations are non-binding. I am not sure how often the FDA follows the advisory panel recommendations.

FDA Rejects Osteoarthritis Drug Arcoxia

1 | 2

Be the first to comment

Related Rheumatoid Arthritis Topics

By Christine Miller, Health Guide— Last Modified: 10/15/11, First Published: 04/11/07

Note: All clinical content on this site is physician-reviewed, except material generated by our community members.

Featuring Content From:

We comply with the HONcode standard for
trustworthy health information: verify here.

By using this service, you accept our Terms of Use. Please read them. The consumer health information on is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2012 Remedy Health Media, LLC. All Rights Reserved.

Healthcentral.com is part of Remedy Health Media

FDA Advisory Panel to Evaluate Arcoxia, a Vioxx Replacement

Ask a Question